Edition:
United States

Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

80.96USD
15 Jul 2019
Change (% chg)

$1.23 (+1.54%)
Prev Close
$79.73
Open
$80.61
Day's High
$81.27
Day's Low
$80.13
Volume
3,038,209
Avg. Vol
3,365,119
52-wk High
$87.07
52-wk Low
$62.09

Latest Key Developments (Source: Significant Developments)

Merck To Acquire Peloton Therapeutics For An Upfront Payment Of $1.05 Billion In Cash
Tuesday, 21 May 2019 06:45am EDT 

May 21 (Reuters) - Merck & Co Inc ::MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK TO ACQUIRE PELOTON THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE.MERCK & CO INC - MERCK, THROUGH A SUBSIDIARY, WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH.MERCK & CO INC - WILL ACQUIRE ALL OUTSTANDING SHARES OF PELOTON IN EXCHANGE FOR AN UPFRONT PAYMENT OF $1.05 BILLION IN CASH..MERCK & CO - PELOTON SHAREHOLDERS ELIGIBLE TO RECEIVE FURTHER $1.15 BILLION CONTINGENT UPON SUCCESSFUL ACHIEVEMENT OF FUTURE MILESTONES FOR CERTAIN CANDIDATES.MERCK & CO INC - ACQUISITION INCLUDES NOVEL LATE-STAGE RENAL CELL CARCINOMA CANDIDATE, PT2977.MERCK & CO INC - COMPANIES ANTICIPATE ACQUISITION WILL CLOSE IN Q3 OF 2019.  Full Article

Third Point LLC Dissolves Share Stake In Merck & Co Inc
Wednesday, 15 May 2019 05:20pm EDT 

May 15 (Reuters) - Third Point LLC::THIRD POINT LLC DISSOLVES SHARE STAKE IN MERCK & CO INC.THIRD POINT LLC: CHANGE IN HOLDINGS ARE AS OF MARCH 31, 2019 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF DECEMBER 31, 2018.  Full Article

Moderna Says Merck Has Elected To Conduct A Phase 1 Clinical Trial For mRNA-1172
Wednesday, 8 May 2019 10:35am EDT 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MODERNA INC - MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.  Full Article

Merck Announces Results From Mid-Stage Trial Of Investigational 15-Valent Pneumococcal Conjugate Vaccine
Wednesday, 8 May 2019 09:00am EDT 

May 8 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES RESULTS FROM PHASE 2 TRIAL OF INVESTIGATIONAL 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (V114) IN INFANTS.MERCK & CO INC - V114 MET PRIMARY ENDPOINT BY DEMONSTRATING NONINFERIORITY TO PCV13 FOR ALL SHARED SEROTYPES, AND AN IMMUNE RESPONSE FOR TWO ADDITIONAL SEROTYPES.MERCK & CO INC - DATA SUPPORT CONTINUED PROGRESSION OF PHASE 3 STUDIES WITH V114.  Full Article

Moderna Inc Entered Into A Fifth Amendment To Collaboration And License Agreement With Merck Sharp & Dohme Corp
Wednesday, 8 May 2019 07:28am EDT 

May 8 (Reuters) - Moderna Inc ::MODERNA INC - ENTERED INTO A FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT WITH MERCK SHARP & DOHME CORP..MODERNA - MERCK HAS ELECTED TO ESTABLISH NEW DEVELOPMENT CANDIDATE FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION AS A NEW “PRODUCT CANDIDATE”,.MERCK HAS ELECTED TO CONDUCT A PHASE 1 CLINICAL TRIAL FOR MRNA-1172.MODERNA - COMPANY IS ELIGIBLE TO RECEIVE AN ADDITIONAL MILESTONE PAYMENT UNLESS MERCK ELECTS NOT TO CONTINUE WITH FURTHER CLINICAL DEVELOPMENT OF MRNA-1172.MODERNA INC - FURTHER DEVELOPMENT OF ORIGINAL DEVELOPMENT CANDIDATE FOR PREVENTION OF RSV PURSUANT TO 2015 MERCK AGREEMENT, MRNA-1777, HAS BEEN PAUSED.MODERNA WILL BE RESPONSIBLE FOR CERTAIN COSTS ASSOCIATED WITH THE CONDUCT OF THE PHASE 1 CLINICAL TRIAL FOR MRNA-1172.  Full Article

Merck’S Belsomra (Suvorexant) C-IV Meets Primary Efficacy Endpoint In Phase 3 Trial
Tuesday, 7 May 2019 06:45am EDT 

May 7 (Reuters) - Merck & Co Inc ::MERCK’S BELSOMRA® (SUVOREXANT) C-IV MEETS PRIMARY EFFICACY ENDPOINT IN PHASE 3 TRIAL FOR THE TREATMENT OF INSOMNIA IN PEOPLE WITH MILD-TO-MODERATE ALZHEIMER’S DISEASE DEMENTIA.MERCK & CO INC - DATA TO BE FILED WITH FDA FOR POTENTIAL INCLUSION IN BELSOMRA PRESCRIBING INFORMATION.MERCK & CO INC - ADVERSE EVENTS WERE RECORDED IN 22.5% (N=32/142) OF PATIENTS IN BELSOMRA GROUP AND 16.1% (N=23/143) IN PLACEBO GROUP.MERCK & CO INC -IN TRIAL, BELSOMRA MET ITS PRIMARY AND SECONDARY EFFICACY ENDPOINTS.MERCK & CO INC - ONE PATIENT IN EACH GROUP DISCONTINUED TREATMENT DUE TO AN ADVERSE EVENT.  Full Article

Merck & Co Inc Approved A New Global Restructuring Program
Tuesday, 30 Apr 2019 06:59am EDT 

April 30 (Reuters) - Merck & Co Inc ::MERCK & CO INC - APPROVED A NEW GLOBAL RESTRUCTURING PROGRAM (THE “2019 RESTRUCTURING PROGRAM”).MERCK & CO INC - ACTIONS CONTEMPLATED UNDER 2019 RESTRUCTURING PROGRAM ARE EXPECTED TO BE SUBSTANTIALLY COMPLETED BY END OF 2023.MERCK & CO INC - CUMULATIVE PRETAX COSTS TO BE INCURRED BY CO TO IMPLEMENT 2019 RESTRUCTURING PROGRAM ESTIMATED TO BE ABOUT $800 MILLION TO $1.2 BILLION.MERCK & CO INC - EXPECTS TO RECORD GAAP CHARGES OF APPROXIMATELY $500 MILLION RELATED TO 2019 RESTRUCTURING PROGRAM IN 2019, INCLUDING $187 MILLION IN Q1.MERCK & CO INC - COMPANY'S NON-GAAP FINANCIAL RESULTS WILL NOT BE AFFECTED BY RESTRUCTURING CHARGES.MERCK- EXPECTS ABOUT 55% OF CUMULATIVE PRETAX COSTS TO RESULT IN CASH OUTLAYS,MOSTLY RELATED TO EMPLOYEE SEPARATION EXPENSE & FACILITY SHUT-DOWN COSTS.  Full Article

Merck & Co Posts Q1 Non-GAAP Earnings Per Share of $1.22
Tuesday, 30 Apr 2019 06:45am EDT 

April 30 (Reuters) - Merck & Co Inc ::MERCK ANNOUNCES FIRST-QUARTER 2019 FINANCIAL RESULTS.Q1 NON-GAAP EARNINGS PER SHARE $1.22.Q1 GAAP EARNINGS PER SHARE $1.12.Q1 EARNINGS PER SHARE ESTIMATE $1.06 -- REFINITIV IBES DATA.FIRST-QUARTER 2019 WORLDWIDE SALES WERE $10.8 BILLION, AN INCREASE OF 8%.COMPANY NARROWS AND RAISES 2019 FULL-YEAR REVENUE RANGE TO BE BETWEEN $43.9 BILLION AND $45.1 BILLION.NARROWS AND RAISES 2019 FULL-YEAR REVENUE RANGE TO BE BETWEEN $43.9 BILLION AND $45.1 BILLION.MERCK & CO SAYS "OUR INVESTMENTS IN RESEARCH AND DEVELOPMENT ARE PAYING OFF".NARROWS AND RAISES 2019 FULL-YEAR GAAP EPS RANGE TO BE BETWEEN $4.02 AND $4.14.QTRLY KEYTRUDA SALES $2,269 MILLION VERSUS $1,464 MILLION.NARROWS AND RAISES 2019 FULL-YEAR NON-GAAP EPS RANGE TO BE BETWEEN $4.67 AND $4.79.QTRLY PROQUAD, M-M-R II AND VARIVAX SALES $496 MILLION VERSUS $392 MILLION.FY2019 EARNINGS PER SHARE VIEW $4.68, REVENUE VIEW $44.42 BILLION -- REFINITIV IBES DATA.QTRLY GARDASIL / GARDASIL 9 SALES $838 MILLION VERSUS $660 MILLION.MERCK - QTRLY GROWTH IN PEDIATRIC VACCINES DRIVEN BY, AMONG OTHERS, M-M-R II, REFLECTING GOVERNMENT TENDERS IN LATAM, HIGHER DEMAND IN EUROPE, U.S..QTRLY ANIMAL HEALTH SALES PERFORMANCE REFLECTS HIGHER DEMAND FOR COMPANION ANIMAL PRODUCTS, PRIMARILY BRAVECTO LINE OF PRODUCTS.MERCK - QTRLY GROWTH IN PEDIATRIC VACCINES ALSO DRIVEN BY PROQUAD, A COMBINATION VACCINE TO HELP PROTECT AGAINST MEASLES, MUMPS, RUBELLA AND VARICELLA.Q1 REVENUE VIEW $10.48 BILLION -- REFINITIV IBES DATA.  Full Article

Applied Lifesciences & Systems Closes $8 Mln Equity Round
Friday, 22 Mar 2019 04:50pm EDT 

March 22 (Reuters) - Applied Lifesciences & Systems::APPLIED LIFESCIENCES & SYSTEMS ANNOUNCES CLOSING OF ITS $8 MILLION SERIES A ROUND OF EQUITY FINANCING.APPLIED LIFESCIENCES & SYSTEMS SAYS CLOSED $8 MILLION ROUND OF EQUITY FINANCING, CO-LED BY MERCK ANIMAL HEALTH AND MOUNTAIN GROUP PARTNERS.  Full Article

EMA Adopts Positive Opinion For Merck's Keytruda For 6-Week Dosing Schedule
Monday, 4 Mar 2019 06:45am EST 

March 4 (Reuters) - Merck & Co Inc ::EUROPEAN MEDICINES AGENCY ADOPTS POSITIVE OPINION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) FOR SIX-WEEK DOSING SCHEDULE ACROSS ALL CURRENT MONOTHERAPY INDICATIONS.MERCK & CO INC - FINAL DECISION ON MARKETING AUTHORIZATION IS EXPECTED IN Q2 OF 2019..  Full Article

Appeals court mulls reviving Merck's $2.54 billion patent win against Gilead

A federal appeals court on Tuesday was considering whether to reinstate a $2.54 billion jury verdict Merck & Co Inc won against Gilead Sciences Inc in a dispute over hepatitis C treatments — the largest ever in a patent infringement case.